The recommendations listed in this clinical practice guideline are, whenever possible,
evidence-based. An initial extensive evidence review, which included literature derived from …

The present document has been conceived as the European update to the American
College of Cardiology (ACC)/American Heart Association (AHA)/ESC 2006 Guidelines for …

Pacemaker treatment for bradyarrhythmia was first approved for national health insurance
coverage in Japan in 1974, and its use rapidly became widespread thereafter …

A unique and highly versatile technique, stress echocardiography (SE) is increasingly
recognized for its utility in the evaluation of non-ischaemic heart disease. SE allows for …

Kardiomiopatie definiuje się jako strukturalne oraz funkcjonalne nieprawidłowości mięśnia
komór, które nie wynikają z niedokrwienia na skutek choroby wieńcowej czy …

Background: The entirely subcutaneous implantable cardioverter-defibrillator (S-ICD) is the
first implantable defibrillator that avoids placing electrodes in or around the heart. Two large …

Aims The totally subcutaneous implantable-defibrillator (S-ICD) is a new alternative to the
conventional transvenous ICD system to minimize intravascular lead complications. There …

Background Implantable cardioverter-defibrillators (ICDs) are implanted with the intention to
prolong life in selected patients with inherited arrhythmia syndromes, but ICD implantation is …

Background—Implantable cardioverter-defibrillator indications in Brugada syndrome remain
controversial, especially in asymptomatic patients. Previous outcome data are limited by …

Background The subcutaneous implantable cardioverter-defibrillator (S-ICD) was developed
to reduce short-and long-term complications associated with transvenous ICD leads. Early …